Wird geladen...
Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non‐small‐cell lung cancer cell lines
MET targeted therapies are under clinical evaluation for non‐small‐cell lung cancer (NSCLC) patients. Tyrosine kinase inhibitors (TKI) against MET have varying degrees of specificity. Tivantinib (ARQ 197) is reported to be a non‐ATP competitive selective MET inhibitor. We aimed to compare the activi...
Gespeichert in:
Veröffentlicht in: | Mol Oncol |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artigo |
Sprache: | Inglês |
Veröffentlicht: |
John Wiley and Sons Inc.
2014
|
Schlagworte: | |
Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5528687/ https://ncbi.nlm.nih.gov/pubmed/25226813 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2014.08.011 |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|